Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute Polish Academy of Sciences 5 Pawinskiego Str., 02-106 Warsaw, Poland., Warsaw, Mazowieckie, Poland
Mrs. Magdalena Chodkowska-Michałowska
Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute Polish Academy of Sciences 5 Pawinskiego Str., 02-106 Warsaw, Poland., Warsaw, Mazowieckie, Poland
The heterogeneity of the mesenchymal stem/stromal cells (MSCs) population poses a challenge to researchers and clinicians, especially those observed at the population level. What is more, the lack of precise evidences regarding MSCs developmental origin even further complicate this issue. As the available evidences indicate several possible pathways of MSCs formation, this diverse origin may be reflected in the unique subsets of cells found within the MSCs population. Such populations differ in specialization degree, proliferation, and immunomodulatory properties or exhibit other additional properties such as increased angiogenesis capacity. In this review article, we attempted to identify such outstanding populations according to the specific surface antigens or intracellular markers. Described groups were characterized depending on their specialization and potential therapeutic application. The reports presented here cover a wide variety of properties found in the recent literature, which is quite scarce for many candidates mentioned in this article. Even though the collected information would allow for better targeting of specific subpopulations in regenerative medicine to increase the effectiveness of MSC-based therapies.
22 February 2024 in Frontiers in Cell and Developmental Biology
Background: High heterogeneity of mesenchymal stem/stromal cells (MSCs) due to different degrees of differentiation of cell subpopulations poses a considerable challenge in preclinical studies. The cells at a pluripotent-like stage represent a stem cell population of interest for many researchers worldwide, which is worthy of identification, isolation, and functional characterization. In the current study, we asked whether Wharton’s jelly-derived MSCs (WJ-MSCs) which express stage-specific embryonic antigen-4 (SSEA-4) can be considered as a pluripotent-like stem cell population.Methods: SSEA-4 expression in different culture conditions was compared and the efficiency of two cell separation methods were assessed: Magnetic Activated Cell Sorting (MACS) and Fluorescence Activated Cell Sorting (FACS). After isolation, SSEA-4+ cells were analyzed for the following parameters: the maintenance of the SSEA-4 antigen expression after cell sorting, stem cell-related gene expression, proliferation potential, clonogenicity, secretome profiling, and the ability to form spheres under 3D culture conditions.Results: FACS allowed for the enrichment of SSEA-4+ cell content in the population that lasted for six passages after sorting. Despite the elevated expression of stemness-related genes, SSEA-4+ cells neither differed in their proliferation and clonogenicity potential from initial and negative populations nor exhibited pluripotent differentiation repertoire. SSEA-4+ cells were observed to form smaller spheroids and exhibited increased survival under 3D conditions.Conclusion: Despite the transient expression of stemness-related genes, our findings could not fully confirm the undifferentiated pluripotent-like nature of the SSEA-4+ WJ-MSC population cultured in vitro.
Neural stem cells (NSCs) hold a very significant promise as candidates for cell therapy due to their robust neuroprotective and regenerative properties. Preclinical studies using NSCs have shown enough encouraging results to perform deeper investigations into more potential clinical applications. Nevertheless, our knowledge regarding neurogenesis and its underlying mechanisms remains incomplete. To understand them better, it seems necessary to characterize all components of neural stem cell niche and discover their role in physiology and pathology. Using NSCs in vivo brings challenges including limited cell survival and still inadequate integration within host tissue. Identifying overlooked factors that might influence these outcomes becomes pivotal. In this review, we take a deeper examination of the influence of a fundamental element that is present in the brain, the cerebrospinal fluid (CSF), which still remains relatively unexplored. Its role in neurogenesis could be instrumental to help find novel therapeutic solutions for neurological disorders, eventually advancing our knowledge on central nervous system (CNS) regeneration and repair.
Nowadays it is observed that the number of stem-cell based experimental therapies in neurodegenerative disorders is massively increasing. Most of the clinical trials registered to date have been based on autologous mesenchymal stem/stromal cells (MSC) obtained from somatic tissues. In the...
Despite ongoing debate surrounding mesenchymal stem/stromal cells (MSCs), the number of clinical trials involving MSCs has continued to increase due to their strong therapeutic potential. These cells exhibit immunosuppressive and neuroprotective properties, making them a promising approach for treating neurodegenerative diseases. Given the growing interest in stem cell-based therapies, it is essential to establish specific protocols for manufacturing adipose-derived MSCs. This study outlines the process of obtaining an ATMP cell product from ASCs, evaluating cell quality, isolation efficiency, and optimal conditions for cryopreservation, preparation, and transport. Cells were isolated from fresh, cryopreserved, and 4°C-stored adipose tissue to evaluate how different storage conditions affect cell quality. In addition, cell viability in different transport solutions over time was examined. To evaluate the therapeutic potential of ASCs, cells were cultured in cerebrospinal fluid (CSF) and neural gene and protein expression, as well as the secretome profile, were analysed. Our findings show that isolating ASCs immediately after liposuction yields the highest viable cell count. Adipose tissue can be stored at 4 °C for up to 48 h without affecting cell population doubling time, but cryopreservation negatively impacts ASCs' clonogenicity. For optimal long-term preservation, a medium with 5 % platelet lysate and 10 % DMSO is recommended. Additionally, we found that 0.9 % NaCl is the best transport medium for maintaining cell viability. CSF exposure induced neural markers (NG2, A2B5, Nestin, β-III-tubulin, S-100-β) and morphological changes, suggesting neural-like differentiation. These findings contribute to the development of protocols for MSC therapy in neurodegenerative diseases.
Extracellular vesicles (EVs) are increasingly being investigated as cell-free therapies for neurological diseases. However, their clinical application remains limited by biological and functional heterogeneity. EVs should therefore not be considered as a single, uniform therapeutic product defined only by their cell of origin, size, or conventional vesicle classification. EV composition and activity are influenced by extrinsic factors, including donor and tissue source, culture conditions, and isolation procedures, as well as by intrinsic mechanisms of vesicle biogenesis and selective cargo loading. Some vesicles may have beneficial therapeutic effects, whereas others may show little biological activity or act on unintended cellular targets. For this reason, EVs may be better classified according to biological function rather than only physical properties or cellular origin. A functionality-based classification could improve potency assessment, dose selection, reproducibility, and the development of consistent EV-based products. EV properties can be modulated by selecting appropriate parental cells, modifying culture conditions, or using genetic or metabolic engineering to alter EV production and cargo. Single-vesicle approaches can reveal differences between EV subpopulations and identify those responsible for specific biological effects. Overall, understanding EV heterogeneity may provide a rational basis for developing reproducible and disease-specific EV therapies for neurological and neurodegenerative disorders.